Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

Early Switch in Moderate ARDS (SWITCH-ARDS)

13 de noviembre de 2026 actualizado por: DEMOSTHENES MAKRIS, University of Thessaly

Early Switch to Assisted Ventilation in Patients With Moderate ARDS: a Physiological Study

The optimal timing for transition from controlled to assisted mechanical ventilation in patients with acute respiratory distress syndrome (ARDS) remains uncertain. Excessive spontaneous respiratory effort may promote injurious transpulmonary pressure swings and heterogeneous regional ventilation, whereas unnecessary prolongation of controlled ventilation may increase sedation exposure and diaphragmatic dysfunction.

This prospective, single-center physiological interventional study will enroll mechanically ventilated adults with ARDS and a PaO₂/FiO₂ ratio >100 and ≤200 mmHg, measured during PEEP=5 cmH2O, who are receiving controlled mechanical ventilation. Participants will undergo a protocolized 30-minute transition from controlled to assisted mechanical ventilation after reduction of sedation sufficient to allow spontaneous respiratory activity.

Respiratory effort and drive, airway and esophageal pressures, respiratory flow, respiratory mechanics, gas exchange, and regional ventilation measured by electrical impedance tomography will be assessed before and during the transition. Participants will subsequently be followed for 48 hours to determine whether assisted ventilation can be maintained without return to fully controlled mechanical ventilation.

Descripción general del estudio

Estado

Reclutamiento

Condiciones

Intervención / Tratamiento

Descripción detallada

Participants meeting eligibility criteria will initially remain on their clinically prescribed controlled mechanical ventilation. Sedation will be gradually reduced to permit the reappearance of spontaneous respiratory activity while avoiding clinically significant agitation or patient-ventilator dyssynchrony. Once spontaneous respiratory activity is present, participants will be transitioned to assisted mechanical ventilation. Positive end-expiratory pressure will be maintained at the pre-transition level, which will have been titrated with the use of esophageal manometry so as to achieve an end-expiratory trans-pulmonary pressure above 0 cmH2O, and inspired oxygen fraction will remain unchanged whenever clinically feasible. Inspiratory assistance will be titrated to maintain protective targets: esophageal pressure swings= 3-15 cmH2O (diaphragm protective) and transpulmonary pressure swings < 15-20 cmH2O (lung protective).

The physiological transition trial will last 30 minutes. Continuous recordings of airway pressure, esophageal pressure, respiratory flow, and electrical impedance tomography will be obtained. Respiratory drive will additionally be assessed using airway occlusion pressure at 100 milliseconds (P0.1).

Three prespecified analysis periods will be used: T0, the final 5 minutes during controlled ventilation before transition; T1, the first 5 minutes of assisted ventilation; and T2, minutes 25-30 of assisted ventilation.

Electrical impedance tomography analyses will include regional distribution of tidal ventilation, global inhomogeneity index, end-expiratory lung impedance, ventral-to-dorsal ventilation distribution, center of ventilation, and occurrence or magnitude of pendelluft. Respiratory mechanics analyses will include esophageal pressure swing, pressure-time product of the esophageal pressure, transpulmonary pressure, respiratory system elastance, chest-wall elastance, and lung elastance.

The transition trial will be stopped if prespecified clinical intolerance or safety criteria occur. Participants who do not tolerate the trial will be returned to controlled ventilation according to clinical requirements.

After completion of the 30-minute trial, participants will be followed for 48 hours. Successful transition will be defined as maintenance of assisted mechanical ventilation without the need to return to fully controlled mechanical ventilation during this period.

Tipo de estudio

De observación

Inscripción (Estimado)

30

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Estudio Contacto

  • Nombre: Apostolos - Alkiviadis Menis, MD, PhD
  • Número de teléfono: +30 2413501280
  • Correo electrónico: menis.ap.alk@proton.me

Copia de seguridad de contactos de estudio

  • Nombre: Demosthenes Makris, MD, PhD
  • Número de teléfono: +30 2413501280
  • Correo electrónico: dimomakris@med.uth.gr

Ubicaciones de estudio

      • Larissa, Grecia
        • Reclutamiento
        • Critical Care Department, University Hospital of Larisa
        • Contacto:

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

18 años y mayores (Adulto, Adulto Mayor)

Acepta Voluntarios Saludables

No

Géneros elegibles para el estudio

Todos

Método de muestreo

Muestra no probabilística

Población de estudio

Patients with ARDS of severe to moderate severity (100<PaO2/FiO2<200 mmHg).

Descripción

Inclusion Criteria:

  • Age ≥18 years
  • Endotracheally intubated and receiving invasive mechanical ventilation
  • Meets diagnostic criteria for acute respiratory distress syndrome
  • PaO₂/FiO₂ ratio >100 and ≤200 mmHg
  • Receiving controlled mechanical ventilation immediately before the transition trial

Exclusion Criteria:

  • Implanted electrical cardiac or other device incompatible with electrical impedance tomography
  • Thoracic drains, extensive dressings, or other factors preventing appropriate EIT belt placement
  • Contraindication to placement of an esophageal balloon catheter
  • Active neuromuscular blockade at initiation of the transition trial
  • Significant hemodynamic instability
  • Any clinical condition for which reduction of sedation or transition to assisted ventilation is considered unsafe by the treating physician

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

  • Modelos observacionales: COHORT
  • Perspectivas temporales: PROSPECTIVE

Cohortes e Intervenciones

Grupo / Cohorte
Intervención / Tratamiento
Experimental: Protocolized Transition to Assisted Mechanical Ventilation

Participants receiving controlled mechanical ventilation will undergo gradual reduction of sedation to permit spontaneous respiratory activity, followed by a 30-minute transition to assisted mechanical ventilation. PEEP will remain at the pre-transition value and FiO₂ will remain unchanged whenever clinically feasible. Inspiratory assistance will be titrated to maintain tidal volume at approximately 6-8 mL/kg predicted body weight. Physiological measurements will be recorded continuously, and the procedure will be terminated if prespecified intolerance or safety criteria occur.

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Difference in Respiratory Mechanics between succesfull and failed transition using a pneumotachograph
Periodo de tiempo: During the first thirty minutes of assisted ventilation.

The investigator will measure the respiratory mechanics at baseline, after the first five minutes of assisted ventilation and at 30 minutes of assisted ventilation. We will measure respiratory rate (breaths per minute).

During the first thirty minutes of assisted ventilation.
Difference in Respiratory Mechanics between succesfull and failed transition using a pneumotachograph
Periodo de tiempo: During the first thirty minutes of assisted ventilation.

The investigator will measure the respiratory mechanics at baseline, after the first five minutes of assisted ventilation and at 30 minutes of assisted ventilation. The measured variables will include the lung elastance, the chest wall elastance and the total respiratory system elastance (all measured in cmH₂O/L).

During the first thirty minutes of assisted ventilation.
Difference in Respiratory Mechanics between succesfull and failed transition using a pneumotachograph
Periodo de tiempo: During the first thirty minutes of assisted ventilation.

The investigator will measure the respiratory mechanics at baseline, after the first five minutes of assisted ventilation and at 30 minutes of assisted ventilation. The measured variables will include the transpulmonary pressure, which is measured in cmH₂O. During the baseline measurement both statics and dynamics measurements will be calculated, whereas during the assisted phase the investigator will include only the dynamic measurements.

During the first thirty minutes of assisted ventilation.
Difference in Respiratory Mechanics between succesfull and failed transition using a pneumotachograph
Periodo de tiempo: During the first thirty minutes of assisted ventilation.

The investigator will measure the respiratory mechanics at baseline, after the first five minutes of assisted ventilation and at 30 minutes of assisted ventilation. We will measure tidal volume (mLs).

During the first thirty minutes of assisted ventilation.

Medidas de resultado secundarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Differences in electrical impedance tomography variables between successful and failed transition to assisted ventilation
Periodo de tiempo: During the first thirty minutes of assisted ventilation.

The investigator will measure the variation in the global inhomogeneity index derived by using electrical impedance tomography.

During the first thirty minutes of assisted ventilation.
Differences in electrical impedance tomography variables between successful and failed transition to assisted ventilation
Periodo de tiempo: During the first 30-minutes of assisted ventilation.

The investigator will measure the end-expiratory lung impedance, EELI, which is measured in ohms.

During the first 30-minutes of assisted ventilation.
Differences in electrical impedance tomography variables between successful and failed transition to assisted ventilation
Periodo de tiempo: During the first 30-minutes of assisted ventilation.

The investigator will measure the ventral to dorsal ratio using the electrical impedance tomography.

During the first 30-minutes of assisted ventilation.
Differences in electrical impedance tomography variables between successful and failed transition to assisted ventilation
Periodo de tiempo: During the first 30-minutes of assisted ventilation.

The investigator will measure the variation in the pendelluft phenomenon using the impedance amplitude values.

During the first 30-minutes of assisted ventilation.
Differences in respiratory effort between successful and failed transition to assisted ventilation
Periodo de tiempo: During the first 30-minutes of assisted ventilation.

The investigator will measure the differences in esophageal pressure swings, ΔPes in cmH₂O, between the beginning of the transition phase and at the final 5 minutes of the 30-minute trial.

During the first 30-minutes of assisted ventilation.
Differences in respiratory effort between successful and failed transition to assisted ventilation.
Periodo de tiempo: During the first 30-minutes of assisted ventilation.

The investigator will measure the differences in the esophageal pressure-time product measured in cmH₂O⋅s/min, between the beginning of the transition phase and at the final 5 minutes of the 30-minute trial.

During the first 30-minutes of assisted ventilation.

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Patrocinador

Investigadores

  • Investigador principal: Apostolos - Alkiviadis Menis, MD, PhD, General University Hospital of Larisa, University of Thessaly
  • Director de estudio: Makris, MD, PhD, General University Hospital of Larisa, University of Thessaly

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Actual)

1 de noviembre de 2026

Finalización primaria (Estimado)

1 de octubre de 2028

Finalización del estudio (Estimado)

1 de diciembre de 2028

Fechas de registro del estudio

Enviado por primera vez

8 de septiembre de 2026

Primero enviado que cumplió con los criterios de control de calidad

23 de octubre de 2026

Publicado por primera vez (Actual)

30 de octubre de 2026

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

16 de noviembre de 2026

Última actualización enviada que cumplió con los criterios de control de calidad

13 de noviembre de 2026

Última verificación

1 de octubre de 2026

Más información

Términos relacionados con este estudio

Otros números de identificación del estudio

  • SWITCH_MODERATE_ARDS

Plan de datos de participantes individuales (IPD)

¿Planea compartir datos de participantes individuales (IPD)?

NO

Información sobre medicamentos y dispositivos, documentos del estudio

Estudia un producto farmacéutico regulado por la FDA de EE. UU.

No

Estudia un producto de dispositivo regulado por la FDA de EE. UU.

No

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .